Total submissions: 4
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Kariminejad - |
RCV001814019 | SCV001755151 | likely pathogenic | Abnormality of the nervous system | 2021-07-10 | criteria provided, single submitter | clinical testing | |
Revvity Omics, |
RCV000032983 | SCV002020806 | pathogenic | Combined oxidative phosphorylation defect type 11 | 2019-09-03 | criteria provided, single submitter | clinical testing | |
Foundation for Research in Genetics and Endocrinology, |
RCV000032983 | SCV004698186 | pathogenic | Combined oxidative phosphorylation defect type 11 | 2024-03-04 | criteria provided, single submitter | clinical testing | A homozygous 5’ splice site variant in intron 2 of the RMND1 gene that affects the invariant GT donor splice site downstream of exon 2 (c.504+1G>A) was detected. The observed variant has previously been reported in patients in affected with Infantile encephalo- neuromyopathy [PMID: 23022099]. The variant has not been reported in the 1000 genomes, gnomAD (v3.1), gnomdAD (v2.1) and topmed databases. The reference region is conserved across species. In summary, the variant meets our criteria to be classified as pahogenic. |
OMIM | RCV000032983 | SCV000056762 | pathogenic | Combined oxidative phosphorylation defect type 11 | 2012-10-05 | no assertion criteria provided | literature only |